Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer

Ya-Fang Wang1,2, Lei Yu3,4, Zong-Long Hu3

  • 1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, PR China. wangyf2@shanghaitech.edu.cn.

Cell Death & Disease
|August 29, 2022
PubMed

Insights

EZH2 inhibitors promote tumor-associated macrophage (TAM) infiltration and M2 polarization in breast cancer by increasing CCL2. EZH2

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Immunology

Background:

  • Tumor-associated macrophages (TAMs) are crucial in cancer progression and drug resistance.
  • Epigenetic regulators influencing TAMs in the tumor microenvironment (TME) are not well understood.

Purpose of the Study:

  • To investigate the role of EZH2 in regulating TAM infiltration and polarization in breast cancer.
  • To elucidate the mechanisms by which EZH2 affects TAMs in the TME.

Main Methods:

  • Utilized EZH2 inhibitors and knockdown in human breast cancer (BC) cells.
  • Assessed M2 macrophage polarization in vitro and in vivo.
  • Analyzed H3K27me3 enrichment on the CCL2 gene promoter.
  • Investigated DNA demethylation and miR-124-3p levels upon EZH2 depletion.

Main Results:

  • EZH2 inhibition in BC cells increased CCL2, promoting M2 TAM polarization and recruitment.
  • EZH2 knockdown led to DNA demethylation and increased miR-124-3p, suppressing CCL2 and arresting M2 TAM polarization.
  • EZH2 exhibits dual regulatory effects on TAM polarization via enzymatic and non-enzymatic activities.

Conclusions:

  • EZH2 plays a critical role in modulating TAMs in breast cancer.
  • Understanding EZH2's impact on TAMs offers insights into EZH2 inhibitor efficacy.
  • Combined therapies targeting EZH2 and TAMs may enhance anti-cancer treatment outcomes.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K